Title Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids /
Authors Seitz, Christian ; Bumbulienė, Žana ; Costa, Ana Rosa ; Heikinheimo, Oskari ; Heweker, Andrea ; Hudeček, Robert ; Jacquemyn, Yves ; Melis, Gian Benedetto ; Parashar, Pooja ; Rechberger, Tomasz ; Sánchez, Antonio Cano ; Aken, Bart van ; Zatik, János ; Gemzell-Danielsson, Kristina
DOI 10.1016/j.cct.2017.02.002
Full Text Download
Is Part of Contemporary clinical trials.. New York : Elsevier Science. 2017, Vol. 55, p. 56-62.. ISSN 1551-7144. eISSN 1559-2030
Keywords [eng] Vilaprisan ; Progesterone receptor modulator ; Uterine fibroids ; Ulipristal acetate ; Amenorrhoea
Abstract [eng] Background: Uterine fibroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the size of UFs. To date, one PRM (ulipristal acetate) has received regulatory approval for the treatment of UFs; therapy comprises intermittent treatment courses of up to 3 months each, followed by a break to allow two menstruations to occur. We report the design of ASTEROID (Assess Safety and efficacy of vilaprisan in patients with uTERine fibrOIDs) 2, a phase 2 study examining the efficacy and safety of a novel PRM, vilaprisan, in women with UFs. Methods/design: In this randomized multi-arm study, vilaprisan (2 mg daily) will be administered in different regimens: continuous treatment for 12 or 24 weeks, or two 12-week treatment periods separated by a break to allow one menstruation to occur. Efficacy and safety will be compared with that of ulipristal acetate (5 mg daily) and placebo. Patients randomized to receive placebo for 12 weeks will also be given active treatment for 12 weeks. The primary measure of efficacy will be amenorrhoea rate; secondary measures include time to normalized menstrual bleeding and percentage change in UF volume. Endometrial changes will be monitored throughout the study. Discussion: The placebo- and active comparator-controlled trial ASTEROID 2 is the first study to evaluate systematically the efficacy and safety of different treatment regimens of PRMs in women with UFs. The findings of this study will direct the planning of future clinical trials of vilaprisan.
Published New York : Elsevier Science
Type Journal article
Language English
Publication date 2017